Navigation Links
Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH
Date:11/14/2011

BASKING RIDGE, N.J., Nov. 14, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announces one poster presentation and two oral presentations at the American Heart Association (AHA) Scientific Sessions meeting on November 14, 2011 during the 9:00 a.m. – 5:00 p.m. EST session.  All three presentations highlight results from Regado's pipeline of antithrombotic agents for the treatment of cardiovascular disease.

Ingo Ahrens, M.D., of University Hospital in Freiburg, Germany, presented "REG1, a Novel RNA-Aptamer Direct Factor IXa-inhibitor Reduces Platelet Activation in Healthy Volunteers and Residual Platelet Aggregation in Patients with ACS.  A RADAR Substudy," at 10:45 a.m. EST.  John Vavalle, M.D., a Fellow in the Division of Cardiology at the Duke University Medical Center, presented further RADAR substudy results in an Abstract Oral Session at 11:15 a.m. EST with a poster titled "The REG1 Anticoagulation System Allows for Early Arterial Sheath Removal After Cardiac Catheterization Without Increases in Time to Hemostasis or Bleeding Complications: An Analysis From the RADAR Clinical Trial."

The above referenced presentations offer substudy analyses of the Company's Phase 2b RADAR clinical trial of REG1, Regado's proprietary anticoagulation system.  The RADAR results demonstrated that REG1 provided nearly complete Factor IXa inhibition with a dose of 1 mg/kg of pegnivacogin and, when followed by 75% and 100% reversal doses of anivamersen, resulted in numerically lower rates of ischemic events when compared with heparin.  The RADAR results clearly support the progression of the development of REG1 to phase 3.   

Dr. Vavalle also presented "Thrombin Generation Kinetics of the REG2 Anticoagulation System: A First-in-Human Experience" at 3 p.m. EST during an Abstract Poster Session. REG2 is Regado's se
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
2. Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
3. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
4. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
5. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
6. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
7. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
8. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
9. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
10. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
11. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today announced that it will ... March 10, 2015. Rob Kill , President and ... will present at 4:00 p.m. Pacific Time and meet ... the Ritz Carlton in Laguna Niguel, CA. ...
(Date:2/27/2015)... 2015  Two mass spectrometry technologies MALDI ... their effectiveness is established, according to biotechnology ... says that while mass spectrometry (mass spec ... in proteomic biomarker discovery and validation, mass ... techniques has struggled to elucidate molecular distribution ...
(Date:2/26/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... the t:slim® and t:flex™ Insulin Pumps, today announced the ... of its common stock at a price to the ... Tandem from this offering are expected to be $56.3 ... estimated offering expenses payable by Tandem. All of the ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3
... CHAPEL HILL, N.C., Oct. 25, 2011 While some ... in today,s crowded, competitive marketplace.   ... new products, companies must think strategically about clinical and ... serve as the gatekeepers to a product,s acceptance in ...
... 2011 The Medical Design Excellence Awards ... from companies and individuals worldwide that are involved in the ... medical packaging products. (Logo:   http://photos.prnewswire.com/prnh/20101214/LA16070LOGO ) ... and sponsored by MD+DI ...
Cached Medicine Technology:Latest Pharmaceutical Launch Strategies Demonstrate Growing Importance of Thought Leader Engagement at Market Entry 2UBM Canon's 2012 Medical Design Excellence Awards Calls for Entries 2
(Date:3/1/2015)... 01, 2015 ERISAPros is ... Carolyn Roddy to the professional staff of its Compliance ... from The Ohio State University-Mortiz College of Law. Prior ... experience working with several Fortune 500 companies as well ... of corporate benefits. Her experiences range from benefit plan ...
(Date:2/28/2015)... Malaysia (PRWEB) February 28, 2015 The ... all across Malaysia into one platform and gears towards ... , A series of group talks in smaller ... like Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, ... and raise awareness of Malaysian youths. , ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 people ... innovative thinking. “The #1 block was lack of ... reports Haman, who created the Thinkubator Innovation Studio in ... that they did not have enough time for innovative ... stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” workshops ...
(Date:2/28/2015)... 28, 2015 March—also known as ... to remind ourselves and others that suspected head ... NeuroSurgical Specialists (ANS). , Concussions are a form ... 75% of TBIs. There are 1.6-3.8 million sports-related ... benign, but it is a brain injury. Many ...
(Date:2/28/2015)... A study out of the University ... procedure for the treatment of a hereditary ocular condition ... Authored by Dr. Robert MacLaren, professor of ophthalmology at ... Medical Journal on January 16, 2014 , the study ... disorder that mostly affects men and leads to the ...
Breaking Medicine News(10 mins):Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2
... is EBCC? , The most exciting breast cancer conference ... all the major players in breast cancer. The conference ... in a partnership of equals to talk not just ... and practical issues associated with caring for patients with ...
... and the,Aronson Foundation, a charitable organization, recently presented a ... The gift,raised from and by Aronson & Company staffers, ... the young patients., Commented Lisa J. Cines, Managing ... further support the hospital in their efforts to help,the ...
... 9 Percent to $12.4 Billion, ARLINGTON HEIGHTS, ... and a looming home lending crisis, average,Americans continue ... the,latest procedural statistics report from the American Society ... surgery procedures were,performed in 2007 - a 7 ...
... Scot Rourke, President and CEO of,OneCommunity, has been ... 2008 by the Intelligent Community Forum (ICF), (http://www.intelligentcommunity.org ... to,studying economic growth in the Broadband Economy., ... in Cleveland, Ohio today.,Rourke will make the Intelligent ...
... Survey Shows Increasing Use of Tiered Copayments, Generics, ... WASHINGTON, March 25 A new survey of,employers ... tools,has helped to slow the cost of prescription ... manager (PBM) tools in increasing savings,and access for ...
... This release is available in German . , , ... these common figures of speech can be taken literally, ... of us would like. For it turns out that intense ... and increase the risk of thrombosis or heart attack. , ...
Cached Medicine News:Health News:An invitation to Europe's largest forum on breast cancer 2Health News:The Aronson Foundation Makes Charitable Donation to Children's Hospital 2Health News:Plastic Surgery Procedures Maintain Steady Growth in 2007 2Health News:OneCommunity's Scot Rourke Named Intelligent Community Visionary of the Year for 2008 2Health News:Employers: Proven PBM Tools Slowing Cost of Prescription Drug Benefits 2Health News:Fear that freezes the blood in your veins 2Health News:Fear that freezes the blood in your veins 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: